Systemic Janus kinase inhibitors in inflammatory dermatoses: A primer for general practitioners.

BACKGROUND: General practitioners (GPs) are increasingly encountering patients treated with novel disease-modifying systemic treatments for chronic inflammatory conditions. The Janus kinase (JAK) signalling pathway has been strongly implicated as a k…

Preview only. Read the full abstract at the source